Showing results (131-140 of 331) with videos related to
Sort By:
Pageof 34
Journal of Biopharmaceutical Statistics|January 30, 2018
Cluster analysis for repeated data with dropout: Sensitivity analysis using a distal eventLiesbeth Bruckers, Geert Molenberghs, Bianca Pulinx, et al.Journal of Biopharmaceutical Statistics|May 25, 2010
A latent pharmacokinetic time profile to model dose-response survival dataTom Jacobs, Roel Straetemans, Geert Molenberghs, et al.Journal of Biopharmaceutical Statistics|October 22, 2013
Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approachMehreteab Aregay, Ziv Shkedy, Geert Molenberghs, et al.BMC Public Health|October 21, 2024
Unraveling the impact of the COVID-19 pandemic on the mortality trends in Belgium between 2020-2022Yessika Adelwin Natalia, Johan Verbeeck, Christel Faes, et al.International Journal of Environmental Research and Public Health|August 26, 2022
The Effect of Transborder Mobility on COVID-19 Incidences in BelgiumFebe Brackx, Fien Vanongeval, Yessika Adelwin Natalia, et al.Journal of the American Veterinary Medical Association|February 13, 2009
Comparison of the guaranteed analysis with the measured nutrient composition of commercial pet foodsRichard C Hill, Christina J Choate, Karen C Scott, et al.Biometrics|August 21, 2003
A local influence approach applied to binary data from a psychiatric studyIvy Jansen, Geert Molenberghs, Marc Aerts, et al.Journal of Biopharmaceutical Statistics|March 31, 2005
A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependentZiv Shkedy, Geert Molenberghs, Hansfried Van Craenendonck, et al.Frontiers in Public Health|November 29, 2023
Key risk factors associated with fractal dimension based geographical clustering of COVID-19 data in the Flemish and Brussels region, BelgiumYessika Adelwin Natalia, Christel Faes, Thomas Neyens, et al.Journal of Biopharmaceutical Statistics|April 5, 2014
Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trialAklilu Habteab Ghebretinsae, Geert Molenberghs, Alex Dmitrienko, et al.Pageof 34